Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 3;12(10):e0069424.
doi: 10.1128/spectrum.00694-24. Epub 2024 Sep 9.

Characterization of acquired β-lactamases in Pseudomonas aeruginosa and quantification of their contributions to resistance

Affiliations

Characterization of acquired β-lactamases in Pseudomonas aeruginosa and quantification of their contributions to resistance

Karl A Glen et al. Microbiol Spectr. .

Abstract

Pseudomonas aeruginosa is a highly problematic opportunistic pathogen that causes a range of different infections. Infections are commonly treated with β-lactam antibiotics, including cephalosporins, monobactams, penicillins, and carbapenems, with carbapenems regarded as antibiotics of last resort. Isolates of P. aeruginosa can contain horizontally acquired bla genes encoding β-lactamase enzymes, but the extent to which these contribute to β-lactam resistance in this species has not been systematically quantified. The overall aim of this research was to address this knowledge gap by quantifying the frequency of β-lactamase-encoding genes in P. aeruginosa and by determining the effects of β-lactamases on susceptibility of P. aeruginosa to β-lactams. Genome analysis showed that β-lactamase-encoding genes are present in 3% of P. aeruginosa but are enriched in carbapenem-resistant isolates (35%). To determine the substrate antibiotics, 10 β-lactamases were expressed from an integrative plasmid in the chromosome of P. aeruginosa reference strain PAO1. The β-lactamases reduced susceptibility to a variety of clinically used antibiotics, including carbapenems (meropenem, imipenem), penicillins (ticarcillin, piperacillin), cephalosporins (ceftazidime, cefepime), and a monobactam (aztreonam). Different enzymes acted on different β-lactams. β-lactamases encoded by the genomes of P. aeruginosa clinical isolates had similar effects to the enzymes expressed in strain PAO1. Genome engineering was used to delete β-lactamase-encoding genes from three carbapenem-resistant clinical isolates and increased susceptibility to substrate β-lactams. Our findings demonstrate that acquired β-lactamases play an important role in β-lactam resistance in P. aeruginosa, identifying substrate antibiotics for a range of enzymes and quantifying their contributions to resistance.IMPORTANCEPseudomonas aeruginosa is an extremely problematic pathogen, with isolates that are resistant to the carbapenem class of β-lactam antibiotics being in critical need of new therapies. Genes encoding β-lactamase enzymes that degrade β-lactam antibiotics can be present in P. aeruginosa, including carbapenem-resistant isolates. Here, we show that β-lactamase genes are over-represented in carbapenem-resistant isolates, indicating their key role in resistance. We also show that different β-lactamases alter susceptibility of P. aeruginosa to different β-lactam antibiotics and quantify the effects of selected enzymes on β-lactam susceptibility. This research significantly advances the understanding of the contributions of acquired β-lactamases to antibiotic resistance, including carbapenem resistance, in P. aeruginosa and by implication in other species. It has potential to expedite development of methods that use whole genome sequencing of infecting bacteria to inform antibiotic treatment, allowing more effective use of antibiotics, and facilitate the development of new antibiotics.

Keywords: Pseudomonas aeruginosa; beta-lactamases; carbapenemase; carbapenems; cephalosporins; horizontal gene transfer; mobile genetic elements; monobactams; penicillins; tazobactam.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig 1
Fig 1
Phylogenetic tree of representative β-lactamase containing P. aeruginosa isolates. The tree comprises 37 isolates with acquired β-lactamases and 27 isolates with no acquired β-lactamases (Table S3). The identities of the β-lactamases are shown. Meropenem-resistant isolates are shown in red, meropenem-susceptible isolates in green, and isolates with unknown phenotype in black. Five P. aeruginosa reference strains (in blue) are also included (59). Sequence types (ST) are shown.

References

    1. Hilliam Y, Kaye S, Winstanley C. 2020. Pseudomonas aeruginosa and microbial keratitis. J Med Microbiol 69:3–13. doi:10.1099/jmm.0.001110 - DOI - PubMed
    1. Nathwani D, Raman G, Sulham K, Gavaghan M, Menon V. 2014. Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist Infect Control 3:32. doi:10.1186/2047-2994-3-32 - DOI - PMC - PubMed
    1. Bassetti M, Vena A, Croxatto A, Righi E, Guery B. 2018. How to manage Pseudomonas aeruginosa infections. Drugs Context 7:1–18. doi:10.7573/dic.212527 - DOI - PMC - PubMed
    1. Bassetti M, Vena A, Russo A, Croxatto A, Calandra T, Guery B. 2018. Rational approach in the management of Pseudomonas aeruginosa infections. Curr Opin Infect Dis 31:578–586. doi:10.1097/QCO.0000000000000505 - DOI - PubMed
    1. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S, National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities . 2013. Antimicrobial-resistant pathogens associated with healthcare-associated infections summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2009–2010. Infect Control Hosp Epidemiol 34:1–14. doi:10.1086/668770 - DOI - PubMed

MeSH terms

LinkOut - more resources